These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
341 related articles for article (PubMed ID: 31685491)
21. Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. Goldberg AD; Atallah E; Rizzieri D; Walter RB; Chung KY; Spira A; Stock W; Tallman MS; Cruz HG; Boni J; Havenith KEG; Chao G; Feingold JM; Wuerthner J; Solh M Leuk Res; 2020 Aug; 95():106385. PubMed ID: 32521310 [TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety Exposure-Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma. Hess B; Townsend W; Ai W; Stathis A; Solh M; Alderuccio JP; Ungar D; Liao S; Liao L; Khouri L; Zhang X; Boni J AAPS J; 2021 Dec; 24(1):11. PubMed ID: 34893942 [TBL] [Abstract][Full Text] [Related]
23. CD25-targeted antibody-drug conjugate camidanlumab tesirine for relapsed or refractory classical Hodgkin lymphoma. Xu B; Li S; Kang B; Fan S; He Z; Zhou J Invest New Drugs; 2022 Dec; 40(6):1333-1341. PubMed ID: 36074313 [TBL] [Abstract][Full Text] [Related]
24. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619 [TBL] [Abstract][Full Text] [Related]
25. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Jurczak W; Zinzani PL; Gaidano G; Goy A; Provencio M; Nagy Z; Robak T; Maddocks K; Buske C; Ambarkhane S; Winderlich M; Dirnberger-Hertweck M; Korolkiewicz R; Blum KA Ann Oncol; 2018 May; 29(5):1266-1272. PubMed ID: 29444231 [TBL] [Abstract][Full Text] [Related]
26. The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma. Calabretta E; Hamadani M; Zinzani PL; Caimi P; Carlo-Stella C Blood; 2022 Jul; 140(4):303-308. PubMed ID: 35580172 [TBL] [Abstract][Full Text] [Related]
27. The Role of Specific ATP-Binding Cassette Transporters in the Acquired Resistance to Pyrrolobenzodiazepine Dimer-Containing Antibody-Drug Conjugates. Corbett S; Huang S; Zammarchi F; Howard PW; van Berkel PH; Hartley JA Mol Cancer Ther; 2020 Sep; 19(9):1856-1865. PubMed ID: 32669316 [TBL] [Abstract][Full Text] [Related]
28. First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma. Vij R; Nath R; Afar DEH; Mateos MV; Berdeja JG; Raab MS; Guenther A; Martínez-López J; Jakubowiak AJ; Leleu X; Weisel K; Wong S; Gulbranson S; Sheridan JP; Reddy A; Paiva B; Singhal A; San-Miguel JF; Moreau P Clin Cancer Res; 2020 May; 26(10):2308-2317. PubMed ID: 31969330 [TBL] [Abstract][Full Text] [Related]
29. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582 [TBL] [Abstract][Full Text] [Related]
30. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study. Michot JM; Bouabdallah R; Vitolo U; Doorduijn JK; Salles G; Chiappella A; Zinzani PL; Bijou F; Kersten MJ; Sarmiento R; Mosulen S; Mendez C; Uttamsingh S; Pourdehnad M; Hege K; Chen T; Klein C; Hagner PR; Nikolova Z; Ribrag V Lancet Haematol; 2020 Sep; 7(9):e649-e659. PubMed ID: 32758434 [TBL] [Abstract][Full Text] [Related]
31. Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study. Caimi PF; Ai WZ; Alderuccio JP; Ardeshna KM; Hamadani M; Hess B; Kahl BS; Radford J; Solh M; Stathis A; Zinzani PL; Wang Y; Qin Y; Wang L; Xu ZC; Carlo-Stella C Haematologica; 2024 Apr; 109(4):1184-1193. PubMed ID: 37646659 [TBL] [Abstract][Full Text] [Related]
32. The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy. Caimi PF; Ardeshna KM; Reid E; Ai W; Lunning M; Zain J; Solh M; Kahl BS; Hamadani M Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e335-e339. PubMed ID: 35034868 [TBL] [Abstract][Full Text] [Related]
33. Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Tannir NM; Forero-Torres A; Ramchandren R; Pal SK; Ansell SM; Infante JR; de Vos S; Hamlin PA; Kim SK; Whiting NC; Gartner EM; Zhao B; Thompson JA Invest New Drugs; 2014 Dec; 32(6):1246-57. PubMed ID: 25142258 [TBL] [Abstract][Full Text] [Related]
34. Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study. Morgensztern D; Besse B; Greillier L; Santana-Davila R; Ready N; Hann CL; Glisson BS; Farago AF; Dowlati A; Rudin CM; Le Moulec S; Lally S; Yalamanchili S; Wolf J; Govindan R; Carbone DP Clin Cancer Res; 2019 Dec; 25(23):6958-6966. PubMed ID: 31506387 [TBL] [Abstract][Full Text] [Related]
35. Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma. Davis JA; Shockley A; Glode AE J Oncol Pharm Pract; 2022 Apr; 28(3):686-690. PubMed ID: 35037773 [No Abstract] [Full Text] [Related]
36. Phase I Study of a CD45-Targeted Antibody-Radionuclide Conjugate for High-Risk Lymphoma. Cassaday RD; Press OW; Pagel JM; Rajendran JG; Gooley TA; Fisher DR; Holmberg LA; Miyaoka RS; Sandmaier BM; Green DJ; Gopal AK Clin Cancer Res; 2019 Dec; 25(23):6932-6938. PubMed ID: 31481510 [TBL] [Abstract][Full Text] [Related]
38. [New drug approval : Loncastuximab tesirine in diffuse large B-cell lymphoma relapsed/refractory after two lines of treatment]. Tauveron-Jalenques U; Bay JO Bull Cancer; 2023 May; 110(5):476-477. PubMed ID: 36949000 [No Abstract] [Full Text] [Related]
39. Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trial. Lin N; Sun X; Zhou H; Zou L; Zhou K; Liu L; Yang H; Hu K; Cai Q; Liu Y; Jin J; Zhang L; Li W; Guo Y; Yang W; Luo F; Wang Z; Zhu R; Yang L; Song D; Song Y; Zhu J Haematologica; 2024 Sep; ():. PubMed ID: 39234866 [TBL] [Abstract][Full Text] [Related]
40. A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy. Trnĕný M; Verhoef G; Dyer MJ; Ben Yehuda D; Patti C; Canales M; Lopez A; Awan FT; Montgomery PG; Janikova A; Barbui AM; Sulek K; Terol MJ; Radford J; Guidetti A; Di Nicola M; Siraudin L; Hatteville L; Schwab S; Oprea C; Gianni AM Haematologica; 2018 Aug; 103(8):1351-1358. PubMed ID: 29748443 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]